$MEDP

Brady Kevin M. sold $2.1M of MEDP

Brady Kevin M. (CFO & Treasurer) sold 3,400 shares of Medpace Holdings, Inc. (MEDP) at $625.24 ($2.13M total) on 2026-08-20.

Original reporting
SEC EDGAR · Brady Kevin M.
Published Aug 24, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, though the amount is modest relative to the company's market cap.

02

Market read

Provides fresh insider‑sale data for MEDP, useful for short‑term traders monitoring executive actions.

03

What to watch

The CFO's sale coincides with a high share price ($625), which may simply reflect personal liquidity needs.

Relevance 6/10Novelty 7/10Timing: filed today

Background

Form 4 filings disclose insider transactions; this filing reports a CFO's open‑market sale of MEDP shares.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

CFO Brady Kevin M. sold 3,400 MEDP shares for $2.1M, reducing his stake to 12,830 shares.

Expected impact

Possible modest downside of 1‑2% in the next few days.

Evidence & confidence

A $2.1M sale by a senior officer is material but not large enough to trigger a sharp move; market may view it as a routine liquidity event.

Market effects

Minimal impact on the broader biotech sector; insider sales are common and rarely affect sector sentiment.

None

Low

Counterpoint

The sale could be a routine portfolio rebalancing rather than a lack of confidence, so the stock may remain stable.

Key entities

  • Medpace Holdings, Inc.

    US‑listed clinical‑trial services provider (ticker MEDP).

  • Brady Kevin M.

    Chief Financial Officer and Treasurer of Medpace.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.